Glycolipids and pharmaceutical compositions thereof for use in therapy

Patent metadata

Field	Value
Publication number	US-11248016-B2
Application number	US-201916522216-A
Country	US
Kind code	B2
Filing date	Jul 25, 2019
Priority date	Apr 4, 2014
Publication date	Feb 15, 2022
Grant date	Feb 15, 2022

Abstract

The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitising or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorder which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.

First claim

The invention claimed is:

1. A compound having the structure

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent or excipient.

3. A nutraceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof together with a nutraceutically acceptable carrier, diluent or excipient.

4. A kit comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and an anti-cancer agent, wherein the anti-cancer agent is provided in a form suitable for, and/or with instructions for, administration in a daily dosage which is significantly reduced compared to the dosage of the anti-cancer agent if administered alone.

5. A method for the treatment of a subject having a disease or condition selected from the group consisting of cancer, autistic spectrum disorders, Alzheimer's disease, Parkinson's disease, Huntington's disease, muscle wasting and viral infection, the method comprising administering a compound of claim 1 to the subject.

6. The method of claim 5 , wherein the compound is selected from the group consisting of an inhibitor of protein translation, a chemotherapeutic agent, a cell sensitising agent, an antiproliferative agent, an antiviral agent and an adjuvant.

Assignees

• Univ Nottingham

Inventors

• Bottley Andrew
• Hayes Christopher
• Seymour Graham
• Grabowska Anna
• Clarke Philip

Classifications

• A61P31/12

  Antivirals · CPC title

• A61K31/7032

  attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K45/06 Primary

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title